What's Happening?
Amgen announced that its cholesterol-lowering drug, Repatha, has shown effectiveness in preventing heart disease-related deaths, heart attacks, and strokes in a 12,000-patient trial. The drug, a PCSK9 inhibitor, has been available since 2015 and generated $2.2 billion in sales in 2024. The study's results could expand Repatha's market reach, as it demonstrates benefits for a broader population beyond those with existing heart conditions.
Why It's Important?
The positive trial results for Repatha could lead to increased adoption of PCSK9 inhibitors, potentially transforming the treatment landscape for cardiovascular diseases. This development may drive competition in the pharmaceutical industry and influence healthcare providers' prescribing practices. The findings also highlight the importance of addressing unmet needs in cholesterol management.
